finasteride + alfuzosin

Finasteride + alfuzosin is a fixed-dose combination of two small molecule drugs used primarily for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Finasteride is a 5-alpha-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), leading to decreased prostate volume and symptom improvement. Alfuzosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the bladder neck and prostate, improving urine flow and reducing BPH symptoms. The combination aims to provide both rapid symptomatic relief from alfuzosin and long-term reduction in prostate size from finasteride. Clinical studies have shown significant improvements in symptom scores and urinary flow rates with this regimen[1][2][5].